CTSO Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of -27.1% compared to CytoSorbents's net margin of -121.19%. CytoSorbents's return on equity of -103.21% beat Exact Sciences's return on equity of -34.11%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 400%. On the other hand Exact Sciences has an analysts' consensus of $68.89 which suggests that it could grow by 58.55%. Given that CytoSorbents has higher upside potential than Exact Sciences, analysts believe CytoSorbents is more attractive than Exact Sciences.

CytoSorbents has a beta of 1.167, which suggesting that the stock is 16.732% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.136, suggesting its more volatile than the S&P 500 by 13.608%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Exact Sciences quarterly revenues of $713.4M. CytoSorbents's net income of -$2.3M is higher than Exact Sciences's net income of -$864.6M. Notably, CytoSorbents's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.56x versus 2.90x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -27.1% compared to CytoSorbents's net margin of 16.94%. CytoSorbents's return on equity of -103.21% beat Illumina's return on equity of -35.09%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 400%. On the other hand Illumina has an analysts' consensus of $130.64 which suggests that it could grow by 66.66%. Given that CytoSorbents has higher upside potential than Illumina, analysts believe CytoSorbents is more attractive than Illumina.

CytoSorbents has a beta of 1.167, which suggesting that the stock is 16.732% more volatile than S&P 500. In comparison Illumina has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.551%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Illumina quarterly revenues of $1.1B. CytoSorbents's net income of -$2.3M is lower than Illumina's net income of $187M. Notably, CytoSorbents's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.56x versus 2.86x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Neuronetics has a net margin of -27.1% compared to CytoSorbents's net margin of -56.29%. CytoSorbents's return on equity of -103.21% beat Neuronetics's return on equity of -178.53%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 400%. On the other hand Neuronetics has an analysts' consensus of $6.83 which suggests that it could grow by 80.78%. Given that CytoSorbents has higher upside potential than Neuronetics, analysts believe CytoSorbents is more attractive than Neuronetics.

CytoSorbents has a beta of 1.167, which suggesting that the stock is 16.732% more volatile than S&P 500. In comparison Neuronetics has a beta of 1.975, suggesting its more volatile than the S&P 500 by 97.503%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neuronetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Neuronetics pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Neuronetics quarterly revenues of $22.5M. CytoSorbents's net income of -$2.3M is higher than Neuronetics's net income of -$12.7M. Notably, CytoSorbents's price-to-earnings ratio is -- while Neuronetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.56x versus 1.60x for Neuronetics. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -27.1% compared to CytoSorbents's net margin of -14.37%. CytoSorbents's return on equity of -103.21% beat Star Equity Holdings's return on equity of -17.45%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 400%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 323.73%. Given that CytoSorbents has higher upside potential than Star Equity Holdings, analysts believe CytoSorbents is more attractive than Star Equity Holdings.

CytoSorbents has a beta of 1.167, which suggesting that the stock is 16.732% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.205%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.6M, which are smaller than Star Equity Holdings quarterly revenues of $17.1M. CytoSorbents's net income of -$2.3M is higher than Star Equity Holdings's net income of -$2.5M. Notably, CytoSorbents's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.56x versus 0.14x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.